Glaukos Corp. (GKOS) shares reached an all-time high of $190.27 on Thursday, extending a rally that has pushed the medical technology company’s market capitalization to $11.03 billion.
The stock’s 111.6% gain over the past 12 months reflects strong operational performance, including a 41.55% increase in revenue for the trailing year through Q2 2026. The company reported total revenue of $185.6 million in the second quarter, a 49.5% year-over-year expansion and ahead of the $151.13 million consensus estimate.
Analysts have responded with upward revisions to price targets. H.C. Wainwright raised its target to $195, while Stifel lifted its projection to $190 and suggested a valuation of $1.0 billion or more by 2027, citing positive momentum for products iDose and Epioxa. Needham set a target of $201, and Truist Securities increased its forecast to $215, emphasizing the valuation potential of the iDose platform and the broader glaucoma business.
InvestingPro, an analysis platform, noted that 11 analysts have revised earnings estimates upward for the upcoming period. The platform also flagged the stock as among the most overvalued relative to its Fair Value, placing it on its Most Overvalued list.
